Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft

Pourrajab, Fatemeh; Velashani, Fereshteh Torkian; Khanaghaei, Masoud; Hekmatimoghaddam, Seyedhossein; Rahaie, Mahdi; Zare-Khormizi, Mohamad Reza

doi:10.1016/j.jpba.2016.11.014

Cited by 12 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 29 , showing correlations of peak plasma concentrations of miR-499, miR-133a, and miR-133b with cardiac troponin I concentrations after CABG. In our patients, the correlation of plasma miR-499 and troponin I concentration persisted for at least 24 hours after surgery and a strong correlation of plasma miR-499 and troponin I concentrations even on day 4 post surgery has recently been reported 16 . Since cardiac troponins I and T are released from necrotic myocardium and both represent specific and sensitive biomarkers for myocardial damage 30 , our data thus support that miR-133a and miR-499 may also be used as circulating biomarkers for perioperative myocardial injury during CABG.…”

Section: Discussionsupporting

confidence: 74%

“…Coronary artery-bypass-graft (CABG) surgery is intrinsically associated with myocardial damage and miRNAs that have been associated with ACS, AMI or HF are altered as well during surgery 14 – 16 . In a mouse model of myocardial infarction, expression of miR-1, miR-133a, miR-208, and miR-499 is decreased in infarcted myocardium and it has been suggested that increased concentrations of serum miR-133a in patients derive from injured myocardium 17 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Establishment of an easy and straight forward heparinase protocol to analyse circulating and myocardial tissue micro-RNA during coronary artery-bypass-graft surgery

Engler

Dreja

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Coronary artery-bypass-graft (CABG) surgery is associated with myocardial damage and increased blood concentrations of circulating microRNAs (miRNA). However, whether and to what extent these miRNAs relate to cardiac tissue miRNA expression have not yet been explored. Since plasma miRNA quantification in samples from cardiopulmonary bypass (CPB) patients is severely hampered by heparin, we established and validated successfully a protocol to reliably measure miRNA in 49 heparinized patients undergoing CABG so as to investigate the relationship between circulating and right atrial miRNAs. Plasma and right atrial expression of miR-1, miR-133a, miR-423-5p, and miR-499 were measured before and after CPB, as well as miRNAs in plasma 24 h thereafter. All plasma miRNAs increased significantly with surgery while cardiac tissue expression of only miR-133a (1.4-fold; p = 0.003) and miR-423-5p (1.3 fold; p = 0.025) increased as well. Right atrial and plasma miR-133a expression correlated positively before CPB (r = 0.288, p = 0.045) but miR-499 expression inversely (r = −0.484, p = 0.0004). There was a strong association between plasma miR-133a and miR-499 concentrations and postoperative troponin I concentrations, the marker for myocardial damage. Increased myocardial miR-133a and miR-423-5p expression together with unchanged miR-1 and miR-499 expression might suggest active release of these miRNAs rather than their origin from damaged cells.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Establishment of an easy and straight forward heparinase protocol to analyse circulating and myocardial tissue micro-RNA during coronary artery-bypass-graft surgery

Engler

Dreja

et al. 2018

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Twenty two 56,58,61,62,64,84,102,110,115,121,133,135,137,141,142,144,148,150,157,159,161,175 of the 37 included studies were conducted in Europe (seven in the UK 56,61,64,115,159,161,175 ), five were conducted in Australia and New Zealand, 68,88,139,147,171 six were conducted in the USA, 87,89,101,165,176,177 three were conducted in East Asia 72,100,117 and one was a worldwide study. 80 Twenty seven of the 37 included studies reported receiving some support from test manufacturers, including supply of assay kits 56,58,61,64,68,72,80,84,…”

Section: Overview Of Included Studiesmentioning

confidence: 99%

High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation

Westwood

Ramaekers

Grimm

et al. 2021

Health Technol Assess

View full text Add to dashboard Cite

Background Early diagnosis of acute myocardial infarction is important, but only 20% of emergency admissions for chest pain will actually have an acute myocardial infarction. High-sensitivity cardiac troponin assays may allow rapid rule out of myocardial infarction and avoid unnecessary hospital admissions. Objectives To assess the clinical effectiveness and cost-effectiveness of high-sensitivity cardiac troponin assays for the management of adults presenting with acute chest pain, in particular for the early rule-out of acute myocardial infarction. Methods Sixteen databases were searched up to September 2019. Review methods followed published guidelines. Studies were assessed for quality using appropriate risk-of-bias tools. The bivariate model was used to estimate summary sensitivity and specificity for meta-analyses involving four or more studies; otherwise, random-effects logistic regression was used. The health economic analysis considered the long-term costs and quality-adjusted life-years associated with different troponin testing methods. The de novo model consisted of a decision tree and a state–transition cohort model. A lifetime time horizon (of 60 years) was used. Results Thirty-seven studies (123 publications) were included in the review. The high-sensitivity cardiac troponin test strategies evaluated are defined by the combination of four factors (i.e. assay, number and timing of tests, and threshold concentration), resulting in a large number of possible combinations. Clinical opinion indicated a minimum clinically acceptable sensitivity of 97%. When considering single test strategies, only those using a threshold at or near to the limit of detection for the assay, in a sample taken at presentation, met the minimum clinically acceptable sensitivity criterion. The majority of the multiple test strategies that met this criterion comprised an initial rule-out step, based on high-sensitivity cardiac troponin levels in a sample taken on presentation and a minimum symptom duration, and a second stage for patients not meeting the initial rule-out criteria, based on presentation levels of high-sensitivity cardiac troponin and absolute change after 1, 2 or 3 hours. Two large cluster randomised controlled trials found that implementation of an early rule-out pathway for myocardial infarction reduced length of stay and rate of hospital admission without increasing cardiac events. In the base-case analysis, standard troponin testing was both the most effective and the most costly. Other testing strategies with a sensitivity of 100% (subject to uncertainty) were almost equally effective, resulting in the same life-year and quality-adjusted life-year gain at up to four decimal places. Comparisons based on the next best alternative showed that for willingness-to-pay values below £8455 per quality-adjusted life-year, the Access High Sensitivity Troponin I (Beckman Coulter, Brea, CA, USA) [(symptoms > 3 hours AND < 4 ng/l at 0 hours) OR (< 5 ng/l AND Δ < 5 ng/l at 0 to 2 hours)] would be cost-effective. For thresholds between £8455 and £20,190 per quality-adjusted life-year, the Elecsys® Troponin-T high sensitive (Roche, Basel, Switzerland) (< 12 ng/l at 0 hours AND Δ < 3 ng/l at 0 to 1 hours) would be cost-effective. For a threshold > £20,190 per quality-adjusted life-year, the Dimension Vista® High-Sensitivity Troponin I (Siemens Healthcare, Erlangen, Germany) (< 5 ng/l at 0 hours AND Δ < 2 ng/l at 0 to 1 hours) would be cost-effective. Conclusions High-sensitivity cardiac troponin testing may be cost-effective compared with standard troponin testing. Study registration This study is registered as PROSPERO CRD42019154716. Funding This project was funded by the National Institute for Health Research (NIHR) Evidence Synthesis programme and will be published in full in Health Technology Assessment; Vol. 25, No. 33. See the NIHR Journals Library website for further project information.

show abstract

“…TEs play a dual role in cells through inducing RNAi machinery (piRNA/miRNAs/siRNAs pathway) whereby on one side induces anti-aging function and on the other side is giving rise cells to aging/senescence by translocation and genome disintegration ( Figure 4 A and B) [ 29 , 36 , 77 ]. Somatic activation of TEs during aging leads to increased expression of miRNAs and aged-related disorders such as a neuronal decline in the brain and cardiac disorders in the cardiovascular system ( Figure 4 B) [ 99 , 100 ]. In humans, somatic transposition of LINEs (e.g.…”

Section: Lifespan and Mechanism By Tes In Agingmentioning

confidence: 99%

“…The somatic activity of piRNA pathway is an evolutionary tool conferring longevity and regeneration capacity in immortal systems [ 29 , 35 , 99 ]. Accordingly, in soma, retroelements become progressively active during the lifespan [ 35 , 55 , 100 ], wherein enforcing endo-siRNAs or miRNAs machinery to come to function and contribute to TE repression. However, they are not as efficient as the piRNA pathway in silencing TEs due to two factors: they repress TE transcripts only when TE is transcribed and processed, and has a reduced capacity to pack silenced TEs into heterochromatin.…”

Section: Lifespan and Mechanism By Tes In Agingmentioning

confidence: 99%

Transposable elements, contributors in the evolution of organisms (from an arms race to a source of raw materials)

Pourrajab

Hekmatimoghaddam

2021

Heliyon

Self Cite

View full text Add to dashboard Cite

There is a concept proposing that the primitive lineages of prokaryotes, eukaryotes, and viruses emerged from the primordial pool of primitive genetic elements. In this genetic pool, transposable elements (TEs) became a source of raw material for primitive genomes, tools of genetic innovation, and ancestors of modern genes (e.g. ncRNAs, tRNAs, and rRNAs). TEs contributed directly to the genome evolution of three forms of life on the earth. TEs now appear as tools that were used to giving rise to sexual dimorphism and sex determination, lineage-specific expression of genes and tissue differentiation and finally genome stability and lifespan determination.

show abstract

Comparison of miRNA signature versus conventional biomarkers before and after off-pump coronary artery bypass graft

Cited by 12 publications

References 28 publications

Establishment of an easy and straight forward heparinase protocol to analyse circulating and myocardial tissue micro-RNA during coronary artery-bypass-graft surgery

Establishment of an easy and straight forward heparinase protocol to analyse circulating and myocardial tissue micro-RNA during coronary artery-bypass-graft surgery

High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation

Transposable elements, contributors in the evolution of organisms (from an arms race to a source of raw materials)

Contact Info

Product

Resources

About